Inauguration of CMA Terminals Khalifa Port Boosts the Port’s Total Container Capacity by 23% to almost 10m TEUs
With the new CMA CGM Terminal, Khalifa Port becomes the regional hub headquarters for three of world’s top five shipping companiesCMA Terminals Khalifa Port will play a vital role in enhancing UAE inland and maritime connectivityThe sustainably designed container terminal is operated under a 35-year concession by a joint venture between CMA CGM & AD Ports GroupThe completed phase 1 of CMA Terminals Khalifa Port cost AED 3.1 billion (USD 845 million), and adds 1.8 million TEUs capacity to Khalifa Port
AD Ports Group (ADPORTS:ADX), an enabler of integrated trade, transport and logistics solutions, announced the inauguration of CMA Terminals Khalifa Port, a state-of-the-art, AED 3.1 billion (USD 845 million) container terminal by His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212510462/en/

HH Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Rodolphe Saadè, Captain Mohamed Al Shamisi during the inauguration of CMA Terminals Khalifa Port (Photo: AETOSWire)
The inauguration is a major milestone in the development of Khalifa Port, AD Ports Group’s flagship port. The world-class container, ro-ro, and multipurpose port facility opened in December 2012, and in just 12 years has expanded to become one of the world’s fastest-growing, most efficient commercial ports.
CMA Terminals Khalifa Port, managed by a joint venture between the CMA CGM Group’s subsidiary CMA Terminals (70%) and AD Ports Group (30%), showcases advanced port infrastructure, including automated gates and integrated systems that enhance efficiency and sustainability. The facility offers shore-power for vessels to limit emissions, several solar panels areas contributing to the energy mix of the terminal operations and includes the region’s first net zero carbon administration building, which is powered by renewable energy sources. The building won the Net Zero Building Project of the Year Award in 2022 from the MENA Green Building Awards.
The addition of the CMA CGM facility increases Khalifa Port’s annual container capacity by 23% to almost 10 million TEUs (Twenty Foot Equivalent Units). The new terminal is ready for rail connectivity and will significantly enhance Khalifa Port’s position as a major gateway for the region. The design of the new facility incorporates sustainability principles into the construction which support the UAE’s wider targets for building the circular economy, recycling construction and reducing operational waste.
The new facility includes eight advanced Ship to Shore (STS) cranes, and 20 Electric Rubber Tyred Gantry (e-RTG) cranes, which enhances Khalifa Port’s reputation as one of the world’s most technologically advanced commercial ports, underscoring Abu Dhabi’s role in driving the future of sustainable and smart trade.
H.E. Mohamed Hassan Alsuwaidi, Chairman of AD Ports Group, said: “The inauguration of CMA Terminals Khalifa Port highlights the UAE as a premier investment destination and solidifies its position as a key partner for global players. The new terminal will boost trade flows and foster long-term economic growth in Abu Dhabi and the UAE.”
Rodolphe Saadé, Chairman and Chief Executive Officer of the CMA CGM Group, said: “The inauguration of our new container terminal is a major step in the development of Khalifa Port, consolidating Abu Dhabi's position as a global trade hub. This strategic infrastructure will boost shipping and logistics activities across the region. Together with our partner AD Ports Group, we are pleased to deliver a modern terminal with a strong focus on innovation and sustainability.”
Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO, AD Ports Group, said: “CMA Terminals Khalifa Port will significantly boost Abu Dhabi’s connectivity, reinforcing its vital role on the global trade map and contributing to local economic diversification in line with the vision of our leadership. This new facility places AD Ports Group firmly in the ranks of the world’s leading global port operators. We look forward to a long, mutually beneficial partnership with CMA CGM that brings long-term economic benefits to the UAE and Abu Dhabi, as we work together to build a sustainable global transport future.”
The inauguration of CMA Terminals Khalifa Port marks the completion of Phase 1 of the new terminal project for CMA CGM, with the opening of an initial quay wall of 800 metres 18.5 metres of depth, and 8 STS Cranes adding a total capacity of 1.8 million TEUs (Twenty Foot Equivalent Units) to Khalifa Port.
With the opening of the new CMA CGM facility, Khalifa Port has reached a new stage as one of the region’s leading port trade hubs. Khalifa Port now extends over 6.3 km2, with 41 quay cranes, 159 yard cranes, 11.7 km of quay wall and 3.8 km of breakwater length.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212510462/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom